Cross-Border Department is a pharmaceutical company dedicated to the development and sales of new small molecule drugs. The company cooperates with American professional pharmaceutical companies to have a complete technology platform that can effectively develop lead drugs.

Cross-Border Department is an enterprise integrating the research, development and sales of products in the fields of biological preparations, APIs, pharmaceutical intermediates, fine chemicals, chiral compounds and other fields. Cooperate with a new drug R&D company founded in the United States by a R&D and operations team composed of more than ten PhDs and masters with nearly 20 years of practical experience in new drug R&D. A complete technology platform has been established that can quickly and effectively verify drug targets and screen out drug lead compounds, thereby completing the main work of new drug research and development, such as new drug synthesis, formulation, efficacy evaluation, pharmacology and toxicology, and application. Currently, it is mainly engaged in the research and development of innovative drugs for the treatment of diabetes and cancer with independent intellectual property rights and paid technical services.

Customers are in every corner of the world. The company will further expand the market and vigorously improve the comprehensive level of R&D and production to adapt to the growing needs of various customers.

The company's purpose: There are no excellent ideas in this world, only down-to-earth results. Best quality, best service.